The scope of this review will be limited to an update of chronic renal disease (CRD). In contrast with patients who have acute renal disease, most patients with CRD progressively and irreversibly lose renal mass and the ability to carry out critical renal functions. If untreated, patients will have life-threatening complications develop. Treatment modalities such as dialysis and renal transplantation greatly reduce the risk of such complications, although patients may have a number of treatment-related complications develop. Oral health care providers will encounter patients with CRD and therefore should update their knowledge about (1) the epidemiology, risk factors, and medical management of CRD, (2) the myriad of complications patients with CRD may experience, and (3) contemporary dental/oral management strategies for patients with CRD. A discussion of renal transplantation has been discussed elsewhere 1 and is beyond the scope of this review.
A patient's renal reserve, or the capacity for structural and functional hypertrophy of surviving nephrons, can compensate to a point at which less than 50% of renal function remains. Once the damage is past the point of compensation, patients will begin to experience the signs and symptoms of chronic renal insufficiency (CRI) and, if left untreated, will progress to a state of chronic renal failure (CRF). Ultimately, such patients develop end-stage renal disease (ESRD), an irreversible and potentially fatal condition unless patients undergo dialysis or renal transplantation. Serum creatinine and blood urea nitrogen levels are considered crude measures of renal function and may yield either false-positive or false-negative results. Glomerular filtration rate (GFR) is the most valid parameter of renal function and is a useful marker in gauging disease progression (Table I ). The creatinine clearance is a clinically acceptable approximation of GFR. For a more sensitive calculation of GFR, there are sophisticated-yet time-consuming-tests measuring inulin clearance (the gold standard for GFR measurement) and clearance of radioisotopes such as 125 I-iothalamate, 51 Cr-EDTA, or 99m Tc-DPTA.
The NHANES III study 2 from 1988-1994 screened noninstitutionalized patients' serum creatinine levels as a crude measure of renal function and estimated that more than 6 million Americans over the age of 12 years had creatinine levels greater than or equal to 1.5 mg/dL. In 1998, 85,520 Americans were diagnosed with ESRD, an incidence rate of 308 per million US citizens. The prevalence of ESRD in 1998 was 323,821, a rate of 1160 per million US citizens. More importantly, there has been a gradual and worrisome increase in the incidence rates over the last decade, reflected primarily in the increasing incidence of diabetes mellitus-the single greatest cause of CRDin the United States. Table II stratifies these statistics by age, sex, race, and cause.
In 1998, 71% of patients with ESRD were undergoing dialysis and 29% had functioning transplants. Although chronic ambulatory peritoneal dialysis is still prescribed, almost 90% of dialysis today is through hemodialysis. Of the 63,000 deaths from ESRD in 1998, more than 50% were from cardiovascular complications. Infections are the second most common cause of death in ESRD.
The medical management of patients with CRD depends on the remaining renal function. As the GFR drops, close monitoring of the following is indicated: GFR, blood urea nitrogen, glycemic control in diabetic patients, hypertension control, proteinuria (a significant risk factor for the progression of CRD), hyperlipidemia, electrolyte derangements in CRD (metabolic acidosis, hypocalcemia, hyperphosphatemia, and hyperkalemia), and smoking cessation compliance. Patients with CRI or CRF may respond favorably to dietary interventions-particularly low-protein diets-although the potential for malnutrition exists. 4 Medications, particularly angiotensin-converting enzyme inhibitors, are commonly prescribed for the treatment of underlying hypertension and proteinuria. 5 The use of potentially nephrotoxic medications in patients with compromised kidney function may be contraindicated. In patients with ESRD who rely on dialysis, the benefit of dialysis outweighs the risk of life-threatening uremic complications, but this modality can lead to numerous complications of importance to the dentist.
COMPLICATIONS
The kidneys perform a wide range of important functions, the prime function of which is to maintain a stable composition of the fluid-bathing cells by selective retention and elimination of water, electrolytes, and other solutes. In addition, they are important sites for carbohydrate, fat, and protein metabolism, and they play a role in the renin-angiotensin system and in the stimulation of red blood cell production. They also assist in the metabolism and elimination both of drugs and of hormones. The progressive loss of kidney function ultimately results in a clinical syndrome known as uremia, in which failure to adequately perform essential functions leads to the buildup of retained toxins and the development of a myriad of potential problems affecting virtually every organ system. Which blend of complications a patient with CRD will have develop will depend on the underlying cause of the CRD, the remaining renal function, the success and compliance of treatment, and individual variation.
Cardiovascular complications are multifactorial in origin and cause the highest morbidity and mortality in this patient population. This is hardly a surprising fact given that almost 75% of patients have hypertension, 65% have diabetes, 34% have congestive heart failure, and 25% have a history of ischemic heart disease at the time they are diagnosed with CRD. In addition, kidney failure leads to fluid overload, stimulation of the renin-angiotensin system, and other mechanisms, all of which cause secondary hypertension. 6 A shutdown in renal erythropoietin production leads to anemia, putting additional stress on the cardiovascular system to meet oxygen demands, and, if untreated, will result in left ventricular hypertrophy and, ultimately, cardiac failure. 7 Vascular disease (both arteriosclerosis and atherosclerosis) is progressive in renal failure, 8 and hyperkalemia increases the risk for dysrhythmias. Collectively, these factors may lead to the development of potentially life-threatening cardiovascular complications, emphasizing the need for the dentist to carefully assess the patient's cardiovascular status before proceeding with dental treatment.
A predilection for developing infective endocarditis (IE) and vascular access infections in this patient population (particularly in those receiving hemodialysis) as the result of orally induced bacteremia has been suggested in the dental literature. 9 Valvulopathies, particularly calcific valvular disease due to secondary hyperparathyroidism, are common in this population. A multicenter prospective study in France revealed an incidence rate of 15 to 19 patients (per 10,000 dialyzed patients) with a severe valvulopathy requiring surgical intervention, 10 a clear Is there a history of anemia?
Is there a history of bone involvement?
Is there a history of abnormal hemostasis?
Is there a history of a psychiatric disorder?
underestimate of the number of patients with valvulopathies for whom antibiotic prophylaxis would normally be indicated before invasive dental procedures. Widespread use of transesophageal echocardiography has further raised the incidence rates of valvular disease in this population.
Oral disease is prevalent in the renal disease population 11 ; 2 recent studies have detected and implicated viridans streptococci bacteremias as the cause both of vascular access infections 12 and of IE, although the source of the bacterial organisms was not confirmed. 13 However, most episodes of bacteremia resulting in IE or vascular access infections are caused by skin pathogens-predominantly Staphylococcus aureus-associated with repeated vascular access for hemodialysis. Arteriovenous fistulae are fraught with fewer episodes of bacteremia and access infections than are prosthetic bridge grafts composed of polytetrafluoroethylene or tunneled cuffed catheters. 12, 13 Bleeding in patients with uremia is primarily caused by a qualitative platelet dysfunction, leading to faulty platelet aggregation; such bleeding is aggravated by renal anemia. 14 Other than the cardiovascular benefits, patients receiving recombinant human erythropoietin replacement for the treatment of renal anemia were noted to have fewer bleeding problems, explained by a normalization of hematocrit that leads to margination of platelets and an increased opportunity for vessel-wall contact. 15 Although gastrointestinal bleeding is the most common presentation, postoperative bleeding after dental care has been reported. Desmopressin can temporarily reverse the platelet dysfunction by increasing the release of von Willebrand's factor from storage. Conjugated estrogens have also been shown to reverse the platelet dysfunction. For longer-term control, hemodialysis in conjunction with erythropoietin replacement will generally reverse uremic bleeding, although the therapy to prevent vascular access thrombosis (eg, heparin or other anticoagulants) can cause a risk for bleeding, and platelet activation by the dialysis membrane can also result in a risk for bleeding.
It is not uncommon for patients on erythropoietin replacement to develop iron-deficiency anemia because of the depletion of their iron stores that are necessary to produce more hemoglobin. Other adverse effects include hyporesponsiveness to the recombinant erythropoietin as well as hypertension. 16 Patients with uremia are often immunosuppressed and may demonstrate dysfunction of both the cellular and the humoral arms of the immune system. Not only are patients predisposed to bacterial infection, but they also may not exhibit the signs and symptoms of severe infection, such as an elevation in temperature. In patients receiving hemodialysis, most infections are associated with the breach of the mucosal immune system secondary to vascular access. Nosocomial transmission of bloodborne pathogens (HIV and hepatitis B, C, and G) and tuberculosis have been reported in this population, and patients should be evaluated for these diseases.
Safely prescribing drugs to this patient population requires an understanding of drug pharmacokinetics. Recent drug dosing guidelines have been published. 17 During a patient's progressive loss of renal function, drug elimination becomes compromised. For drugs normally eliminated in an unchanged form, reduced glomerular filtration and tubular secretion rates can lead to toxic plasma drug levels (particularly if the drug does not undergo hepatic metabolism), mandating a change in the dosing regimen. If rapid therapeutic drug levels are required, the loading dose normally remains unadjusted unless the patient is hypervolemic. For drugs with a large therapeutic index and half-life-assuming the patient has normal drug absorption and liver function-drug dosage should be adjusted by increasing the interval between doses while preserving dose size. Conversely, for drugs with a narrow therapeutic index or a short half-life, or when a constant blood level is desired, a reduction in dose size while preserving the dose schedule is indicated. 17 Gastrointestinal absorption is compromised by nausea, vomiting, or changes in intestinal pH caused by uremia. Medications, including cationic phosphate binders or iron supplements commonly prescribed to these patients, can also interfere with absorption. Low serum albumin levels may impair plasma protein binding, and concomitant liver dysfunction can lead to diminished drug metabolism.
The extent to which hemodialysis affects blood drug levels primarily depends on when the drug is taken relative to the timing of the dialysis session and the membrane pore size. With the evolution of dialysis technology, the newer "high-flux" membranes have larger pores than the conventional membranes, which may result in an increased clearance of drugs during dialysis and a need for supplemental dosing after dialysis. 18 Despite the fact that most of the medications routinely used in dentistry are relatively safe and are prescribed for short-term use, some medications are nephrotoxic in this population. Numerous reports of nephrotoxicity in patients receiving analgesics led the National Kidney Foundation to develop recommendations for analgesic use in patients with CRD. 19 Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated unless renal function is monitored. Acetaminophen, as a single agent, remains the non-narcotic analgesic of choice for episodic use. The major mechanism explaining the nephrotoxicity of NSAIDs in patients with CRD is a reversible inhibition of renal prostaglandin synthesis resulting in vasoconstriction and reduced perfusion to already compromised kidneys. 20 Case reports have demonstrated that cyclo-oxygenase 2 (COX-2) inhibitors can also cause acute renal failure, 21 although additional studies are needed to ascertain whether these agents have a different nephrotoxicity profile than other NSAIDs.
In patients with CRD, the dosage of medications with a narrower therapeutic index, such as narcotic analgesics (eg, fentanyl, morphine, codeine, and hydrocodone) should be reduced in proportion to the GFR. The primary metabolite of meperidine, if not excreted normally, can precipitate seizures. Correct dosing of antibiotics is crucial to their efficacy, particularly in a population with compromised immune function. To achieve therapeutic levels quickly, volume status rather than renal function should dictate the initial loading dose. Because most antibiotics have a wide therapeutic index (with some exceptions), spacing out the dosage schedule is preferable for future dosing. Once a patient develops CRF (GFR < 30 mL/min), with the exception of penicillin V that requires no adjustment, dosages of penicillins and cephalosporins including amoxicillin (with or without clavulanic acid), ampicillin (with or without sulbactam), and cephalexin should be spaced apart, with intervals adjusted to GFR. The clinician should be aware that high doses of penicillins can lead to drug accumulation risk for seizures. Because these antibiotics are cleared during hemodialysis, additional doses should be given during and after dialysis. Approximately 10% of clindamycin is eliminated unchanged and is not affected by hemodialysis, allowing it to be prescribed in normal doses to patients with CRD. Because of their reported ototoxicity and nephrotoxicity, dosages of erythromycin and tetracycline, respectively, should be adjusted in patients with CRD. Benzodiazepines may be prescribed without adjusting dosage, although excessive sedation is a possibility in patients with ESRD.
Dysfunctional mineral homeostasis, known as renal osteodystrophy, is common in patients with CRD; this condition ranges anywhere from a high to a low state of bone turnover. Secondary hyperparathyroidism, initiated by the kidneys' inability to secrete phosphate, is characterized by increased osteoblastic and osteoclastic activity, leading to osteitis fibrosa in approximately 30% of patients with ESRD. 22 Parathyroidectomy and vitamin D therapy lower parathyroid hormone levels and can reverse secondary hyperparathyroidism. Among other factors, the overuse of vitamin D or calcium-based phosphate binders can lead to adynamic bone disease, a state of low bone turnover occurring in approximately 30% of ESRD patients (especially those patients who are receiving peritoneal dialysis). 23 Aluminum accumulation puts patients at additional risk for osteomalacia, a low state of bone turnover characterized by defective mineralization. Phosphate binders free of calcium and aluminumsuch as sevelamer-are now frequently prescribed. Approximately 10% of ESRD patients show a mixture both of high and of low bone turnover states. Albeit infrequent, there are reports of jawbone involvement, particularly macrognathia 24 ; thus, patients with renal disease should be carefully screened for renal osteodystrophy before performing surgical procedures involving boneparticularly implant placement. 25 The oral manifestations of uremia have been reported to include xerostomia, candidiasis, metallic taste changes, uremic odor, petechiae, ecchymoses, gingival bleeding, and ulcerations (uremic stomatitis), although the prevalence of such manifestations has not been carefully studied. A recent study 26 of 60 patients with ESRD who were undergoing hemodialysis reported that patients with oral manifestations had significantly greater salivary dysfunction (as measured by means of scintigraphy) than did healthy control subjects or patients without oral manifestations.
MANAGEMENT STRATEGIES
The oral/dental management of patients with CRD has 3 components: (1) oral/dental and medical risk assessment, including the identification of existing or potential complications that could affect oral health or dental treatment, (2) treatment modifications customized to ameliorate or prevent such complications, and (3) risk-factor prevention. Furthermore, in patients with uncontrolled diabetes or hypertension, oral health care providers are advised to screen for renal dysfunction.
The oral/dental and medical risk assessment involves a detailed history, intraoral/extraoral soft tissue and radiographic examination, and consultation with a nephrologist or other specialists (eg, endocrinologist). Important data to collect include the following: (1) the degree of CRD, cause, and factors associated with disease progression, (2) the presence and control of comorbid medical conditions such as diabetes, hypertension, and associated sequelae, (3) the modalities of medical treatment, and (4) distant or recent history of renal complications of particular importance to the proposed dental treatment plan, with corroborating laboratory tests and/or signs and symptoms.
A comprehensive risk assessment facilitates the treatment plan. Because so many organ systems are potentially affected by CRD, the reader is encouraged to review suggested dental treatment modifications for patients with cardiovascular disease, bleeding abnormalities, infections, compromised immune systems, and others. Table III summarizes the assessment and management of patients with CRD. The prevention of risk factors, especially tobacco use, is a responsibility the oral health care provider should take seriously; reference materials about tobacco cessation are available to help professionals provide this service to their patients.
